These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8865473)

  • 21. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
    J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
    Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y; Fuse H; Masai M
    Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
    Ornstein DK; Rao GS; Smith DS; Andriole GL
    J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening and early detection for prostate cancer.
    Magoha GA
    East Afr Med J; 1997 Oct; 74(10):664-7. PubMed ID: 9529752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Screening for early detection of prostate cancer (first experience in Israel)].
    Neheman A; Shotland Y; Metz Y; Stein A
    Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
    Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
    Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
    Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer.
    Abdel-Meguid TA; Mosli HA; Al-Maghrabi JA
    Saudi Med J; 2009 Dec; 30(12):1563-7. PubMed ID: 19936421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis and medical management of benign prostatic hyperplasia.
    Appell RA
    Semin Nephrol; 1994 Nov; 14(6):531-43. PubMed ID: 7531869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
    Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
    J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
    Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
    Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.